BB Biotech AG financials
BB Biotech AG
391200MBZQNPFHIVKO34 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Other income | CHF 4.0K | CHF 4.0K |
| Administrative expenses | CHF 38.7M | CHF 52.6M |
| Finance costs | CHF 1.7M | CHF 986.0K |
| Profit before tax | -CHF 357.8M | -CHF 404.7M |
| Income tax expense | CHF 61.0K | CHF 67.0K |
| Profit for the year | -CHF 357.8M | -CHF 404.8M |
| Total comprehensive income | -CHF 357.8M | -CHF 404.8M |
| Per share | ||
| Basic EPS | CHF -6.50 | CHF -7.31 |
| Diluted EPS | CHF -6.50 | CHF -7.31 |
| Cash flow statement | ||
| Net cash from operating activities | CHF 231.1M | -CHF 94.8M |
| Net cash from financing activities | -CHF 233.3M | CHF 91.8M |
| Dividends paid | CHF 212.2M | CHF 199.4M |
| Proceeds from borrowings | CHF 8.0M | CHF 292.0M |
| Balance sheet | ||
| Total assets | CHF 3.05B | CHF 3.64B |
| Current assets | CHF 3.05B | CHF 3.64B |
| Cash & equivalents | CHF 1.9M | CHF 2.8M |
| Total equity | CHF 2.69B | CHF 3.28B |
| Current liabilities | CHF 367.3M | CHF 360.6M |
| Derived metrics | ||
| Return on equity | -13.3% | -12.3% |
| Cash conversion ratio | -0.65× | 0.23× |
| Other reported items | ||
| Current Financial Assets At Fair Value Through Profit Or Loss | CHF 3.05B | CHF 3.64B |
| Current Tax Liabilities Current | CHF 111.0K | CHF 158.0K |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | CHF 2.85 | — |
| Dividends Recognised As Distributions To Owners Per Share | CHF 3.85 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | CHF 1.3M | -CHF 962.0K |
| Equity and Liabilities | CHF 3.05B | CHF 3.64B |
| Finance Income | CHF 4.0K | CHF 0 |
| Income Taxes Paid Refund Classified As Operating Activities | CHF 97.0K | CHF 139.0K |
| Increase Decrease In Cash and Cash Equivalents | -CHF 887.0K | -CHF 4.0M |
| Increase Decrease Through Treasury Share Transactions | -CHF 27.3M | CHF 194.0K |
| Interest Paid Classified As Financing Activities | CHF 1.7M | CHF 986.0K |
| Interest Received Classified As Operating Activities | CHF 4.0K | CHF 0 |
| Issued Capital | CHF 11.1M | CHF 11.1M |
| Liabilities | CHF 367.3M | CHF 360.6M |
| Net Foreign Exchange Gain | CHF 1.3M | CHF 0 |
| Net Foreign Exchange Loss | CHF 0 | CHF 962.0K |
| Other Current Liabilities | CHF 4.1M | CHF 5.4M |
| Other Current Nonfinancial Assets | CHF 92.0K | CHF 135.0K |
| Other Expense By Function | CHF 4.3M | CHF 6.6M |
| Payments To Acquire Or Redeem Entitys Shares | CHF 27.3M | CHF 9.5M |
| Payments To Suppliers For Goods and Services | CHF 44.3M | CHF 59.5M |
| Proceeds From Sale Or Issue of Treasury Shares | CHF 0 | CHF 9.7M |
| Retained Earnings | CHF 2.71B | CHF 3.28B |
| Secured Bank Loans Received | CHF 363.0M | CHF 355.0M |
| Treasury Shares | CHF 36.5M | CHF 9.2M |
Every line item above is a fact tagged in BB Biotech AG's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (CHF), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.